Aptar Supports LTR Pharma's Intranasal Therapy Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 9 hours ago
0mins
Should l Buy ATR?
Source: Newsfilter
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 128.650
Low
133.00
Averages
145.33
High
156.00
Current: 128.650
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
Energy Stocks Flash Momentum Warning for Investors
- Momentum Indicator Warning: As of March 2, 2026, two stocks in the energy sector are signaling momentum warnings, particularly with Relative Strength Index (RSI) values exceeding 70, indicating potential overbought conditions that investors should heed.
- Nordic American Tankers Performance: Nordic American Tankers (NYSE:NAT) reported disappointing quarterly results on February 26, and despite a 37% stock price increase over the past month, its RSI stands at 93.8, suggesting a risk of correction due to overvaluation.
- Price Action Analysis: NAT's shares rose 6.1% to close at $5.73 on Friday, showing strong short-term performance; however, the high RSI indicates potential price adjustments ahead, prompting investors to monitor market developments closely.
- Tsakos Energy Navigation Overview: Tsakos Energy Navigation (NYSE:TEN) is also under scrutiny, with strong momentum scores, although specific data is not disclosed, investors should consider overall market trends and individual stock performance.
See More
River Road Acquires Significant Stake in AptarGroup
- New Investment Position: River Road Asset Management disclosed on February 24, 2026, in an SEC filing that it acquired 917,670 shares of AptarGroup, valued at $111.92 million, indicating confidence in the company's future prospects.
- Ownership Proportion Analysis: This transaction represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, suggesting that AptarGroup is no longer among the fund's top five holdings, which may affect its risk profile.
- Market Performance Review: As of February 28, 2026, AptarGroup's shares traded at $143.71, down 1.32% over the past year, underperforming the S&P 500 by 18.68 percentage points, reflecting market caution regarding its growth potential.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which may attract environmentally-conscious investors despite its current stock performance.
See More
River Road Asset Management Acquires AptarGroup Shares Worth $111.92 Million
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup valued at $111.92 million, marking a new investment position that reflects confidence in AptarGroup's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets as of December 31, 2025, indicating a strategic consideration in diversifying its investment portfolio, which could enhance overall investment returns.
- Performance Growth Outlook: AptarGroup reported a 14% increase in sales in its fourth-quarter report for 2025, with all core segments showing growth, demonstrating the company's competitiveness and sustained profitability, which is likely to attract more investor interest going forward.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which appeals to environmentally conscious investors and further enhances its market attractiveness.
See More
River Road Acquires New Position in AptarGroup with 917,670 Shares
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup (NYSE:ATR) valued at $111.92 million, marking a new investment position that reflects confidence in the company's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, highlighting the significance of AptarGroup within its diversified investment portfolio.
- Financial Performance: AptarGroup reported a 14% year-over-year sales increase in its fourth-quarter report for 2025, with all core segments showing growth, and it has increased dividends for 32 consecutive years, currently yielding 1.29%, indicating strong financial health.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which attracts environmentally conscious investors, and it is expected that its pharma segment will continue to grow robustly, particularly in injectables and consumer healthcare solutions.
See More
Consumer Staples Sector Overbought Warning
- Overbought Signals: As of February 27, 2026, Darling Ingredients Inc (NYSE:DAR) and Coca-Cola Consolidated Inc (NASDAQ:COKE) are flagged as overbought stocks in the consumer staples sector, with RSI indicators exceeding 70, indicating potential price correction risks in the short term, prompting caution among investors.
- RSI Indicator Insights: The Relative Strength Index (RSI), a momentum indicator that compares the strength of stock price increases to decreases, assists traders in assessing short-term performance, and an overbought condition may lead to losses for investors buying at high levels.
- Market Reaction: The emergence of overbought signals may prompt investors to reassess the investment value of these two stocks, potentially leading to short-term capital outflows that could affect overall market sentiment and price movements.
- Investment Strategy Adjustments: Given the current overbought conditions, investors may need to adjust their strategies, considering more attractive buying opportunities during price corrections to mitigate potential risks and optimize their portfolios.
See More
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
Energy Stocks Flash Momentum Warning for Investors
- Momentum Indicator Warning: As of March 2, 2026, two stocks in the energy sector are signaling momentum warnings, particularly with Relative Strength Index (RSI) values exceeding 70, indicating potential overbought conditions that investors should heed.
- Nordic American Tankers Performance: Nordic American Tankers (NYSE:NAT) reported disappointing quarterly results on February 26, and despite a 37% stock price increase over the past month, its RSI stands at 93.8, suggesting a risk of correction due to overvaluation.
- Price Action Analysis: NAT's shares rose 6.1% to close at $5.73 on Friday, showing strong short-term performance; however, the high RSI indicates potential price adjustments ahead, prompting investors to monitor market developments closely.
- Tsakos Energy Navigation Overview: Tsakos Energy Navigation (NYSE:TEN) is also under scrutiny, with strong momentum scores, although specific data is not disclosed, investors should consider overall market trends and individual stock performance.
See More
River Road Acquires Significant Stake in AptarGroup
- New Investment Position: River Road Asset Management disclosed on February 24, 2026, in an SEC filing that it acquired 917,670 shares of AptarGroup, valued at $111.92 million, indicating confidence in the company's future prospects.
- Ownership Proportion Analysis: This transaction represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, suggesting that AptarGroup is no longer among the fund's top five holdings, which may affect its risk profile.
- Market Performance Review: As of February 28, 2026, AptarGroup's shares traded at $143.71, down 1.32% over the past year, underperforming the S&P 500 by 18.68 percentage points, reflecting market caution regarding its growth potential.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which may attract environmentally-conscious investors despite its current stock performance.
See More
River Road Asset Management Acquires AptarGroup Shares Worth $111.92 Million
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup valued at $111.92 million, marking a new investment position that reflects confidence in AptarGroup's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets as of December 31, 2025, indicating a strategic consideration in diversifying its investment portfolio, which could enhance overall investment returns.
- Performance Growth Outlook: AptarGroup reported a 14% increase in sales in its fourth-quarter report for 2025, with all core segments showing growth, demonstrating the company's competitiveness and sustained profitability, which is likely to attract more investor interest going forward.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which appeals to environmentally conscious investors and further enhances its market attractiveness.
See More
River Road Acquires New Position in AptarGroup with 917,670 Shares
- New Investment Position: River Road Asset Management disclosed in an SEC filing dated February 24, 2026, that it acquired 917,670 shares of AptarGroup (NYSE:ATR) valued at $111.92 million, marking a new investment position that reflects confidence in the company's future growth potential.
- Asset Management Proportion: This acquisition represents 1.23% of River Road's 13F reportable assets under management as of December 31, 2025, highlighting the significance of AptarGroup within its diversified investment portfolio.
- Financial Performance: AptarGroup reported a 14% year-over-year sales increase in its fourth-quarter report for 2025, with all core segments showing growth, and it has increased dividends for 32 consecutive years, currently yielding 1.29%, indicating strong financial health.
- Sustainability Commitment: AptarGroup is committed to sourcing 100% of its electricity needs from renewable resources by 2030, aligning with the Science Based Targets Initiative, which attracts environmentally conscious investors, and it is expected that its pharma segment will continue to grow robustly, particularly in injectables and consumer healthcare solutions.
See More
Consumer Staples Sector Overbought Warning
- Overbought Signals: As of February 27, 2026, Darling Ingredients Inc (NYSE:DAR) and Coca-Cola Consolidated Inc (NASDAQ:COKE) are flagged as overbought stocks in the consumer staples sector, with RSI indicators exceeding 70, indicating potential price correction risks in the short term, prompting caution among investors.
- RSI Indicator Insights: The Relative Strength Index (RSI), a momentum indicator that compares the strength of stock price increases to decreases, assists traders in assessing short-term performance, and an overbought condition may lead to losses for investors buying at high levels.
- Market Reaction: The emergence of overbought signals may prompt investors to reassess the investment value of these two stocks, potentially leading to short-term capital outflows that could affect overall market sentiment and price movements.
- Investment Strategy Adjustments: Given the current overbought conditions, investors may need to adjust their strategies, considering more attractive buying opportunities during price corrections to mitigate potential risks and optimize their portfolios.
See More
